<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang Y</submitter><funding>European Research Council</funding><pagination>1296</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5882855</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(1)</volume><pubmed_abstract>Incomplete delivery to the target cells is an obstacle for successful gene therapy approaches. Here we show unexpected effects of incomplete targeting, by demonstrating how heterogeneous inhibition of a growth promoting signaling pathway promotes tissue hyperplasia. We studied the function of the lymphangiogenic VEGFR3 receptor during embryonic and post-natal development. Inducible genetic deletion of Vegfr3 in lymphatic endothelial cells (LECs) leads to selection of non-targeted VEGFR3&lt;sup>+&lt;/sup> cells at vessel tips, indicating an indispensable cell-autonomous function in migrating tip cells. Although Vegfr3 deletion results in lymphatic hypoplasia in mouse embryos, incomplete deletion during post-natal development instead causes excessive lymphangiogenesis. Analysis of mosaically targeted endothelium shows that VEGFR3&lt;sup>-&lt;/sup> LECs non-cell-autonomously drive abnormal vessel anastomosis and hyperplasia by inducing proliferation of non-targeted VEGFR3&lt;sup>+&lt;/sup> LECs through cell-contact-dependent reduction of Notch signaling. Heterogeneity in VEGFR3 levels thus drives vessel hyperplasia, which has implications for the understanding of mechanisms of developmental and pathological tissue growth.</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Heterogeneity in VEGFR3 levels drives lymphatic vessel hyperplasia through cell-autonomous and non-cell-autonomous mechanisms.</pubmed_title><pmcid>PMC5882855</pmcid><funding_grant_id>646849</funding_grant_id><pubmed_authors>Alitalo K</pubmed_authors><pubmed_authors>Makinen T</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Frye M</pubmed_authors><pubmed_authors>Stanczuk L</pubmed_authors><pubmed_authors>Martinez-Corral I</pubmed_authors><pubmed_authors>Ulvmar MH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Heterogeneity in VEGFR3 levels drives lymphatic vessel hyperplasia through cell-autonomous and non-cell-autonomous mechanisms.</name><description>Incomplete delivery to the target cells is an obstacle for successful gene therapy approaches. Here we show unexpected effects of incomplete targeting, by demonstrating how heterogeneous inhibition of a growth promoting signaling pathway promotes tissue hyperplasia. We studied the function of the lymphangiogenic VEGFR3 receptor during embryonic and post-natal development. Inducible genetic deletion of Vegfr3 in lymphatic endothelial cells (LECs) leads to selection of non-targeted VEGFR3&lt;sup>+&lt;/sup> cells at vessel tips, indicating an indispensable cell-autonomous function in migrating tip cells. Although Vegfr3 deletion results in lymphatic hypoplasia in mouse embryos, incomplete deletion during post-natal development instead causes excessive lymphangiogenesis. Analysis of mosaically targeted endothelium shows that VEGFR3&lt;sup>-&lt;/sup> LECs non-cell-autonomously drive abnormal vessel anastomosis and hyperplasia by inducing proliferation of non-targeted VEGFR3&lt;sup>+&lt;/sup> LECs through cell-contact-dependent reduction of Notch signaling. Heterogeneity in VEGFR3 levels thus drives vessel hyperplasia, which has implications for the understanding of mechanisms of developmental and pathological tissue growth.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Apr</publication><modification>2025-05-18T12:42:14.691Z</modification><creation>2025-05-18T12:42:14.691Z</creation></dates><accession>S-EPMC5882855</accession><cross_references><pubmed>29615616</pubmed><doi>10.1038/s41467-018-03692-0</doi></cross_references></HashMap>